BR112018017233A2 - uso de i. butyriciproducens e/ou e. hallii, e, composição - Google Patents

uso de i. butyriciproducens e/ou e. hallii, e, composição

Info

Publication number
BR112018017233A2
BR112018017233A2 BR112018017233A BR112018017233A BR112018017233A2 BR 112018017233 A2 BR112018017233 A2 BR 112018017233A2 BR 112018017233 A BR112018017233 A BR 112018017233A BR 112018017233 A BR112018017233 A BR 112018017233A BR 112018017233 A2 BR112018017233 A2 BR 112018017233A2
Authority
BR
Brazil
Prior art keywords
composition
butyriciproducens
hallii
producing bacteria
vitamin
Prior art date
Application number
BR112018017233A
Other languages
English (en)
Inventor
Meindert De Vos Willem
Original Assignee
Caelus Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caelus Pharmaceuticals B V filed Critical Caelus Pharmaceuticals B V
Publication of BR112018017233A2 publication Critical patent/BR112018017233A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

é ensinado um método para prevenir e/ou tratar deficiência de vitamina b12. o método compreende administrar uma composição compreendendo bactérias produtoras de pseudovitamina b12, opcionalmente junto com bactérias degradadoras de mucina e/ou produtoras de propionato, a um sujeito que precisa da mesma. o método é particularmente adequado para administração a sujeitos que sofrem de deficiência de vitamina b12 em virtude do tratamento com metformina para diabetes tipo 2, e aos sujeitos que passaram por cirurgia bariátrica.
BR112018017233A 2016-02-25 2017-02-27 uso de i. butyriciproducens e/ou e. hallii, e, composição BR112018017233A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2016323 2016-02-25
PCT/NL2017/050119 WO2017146580A1 (en) 2016-02-25 2017-02-27 Compositions and methods for preventing and/or treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
BR112018017233A2 true BR112018017233A2 (pt) 2019-01-15

Family

ID=56507778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018017233A BR112018017233A2 (pt) 2016-02-25 2017-02-27 uso de i. butyriciproducens e/ou e. hallii, e, composição

Country Status (12)

Country Link
US (1) US10857189B2 (pt)
EP (1) EP3419637B1 (pt)
JP (2) JP7012651B2 (pt)
KR (1) KR20180113535A (pt)
CN (1) CN108697742A (pt)
AU (1) AU2017222990A1 (pt)
BR (1) BR112018017233A2 (pt)
CA (1) CA3014525A1 (pt)
ES (1) ES2865477T3 (pt)
RU (1) RU2730870C2 (pt)
SG (1) SG11201807023QA (pt)
WO (1) WO2017146580A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
BR112018017233A2 (pt) 2016-02-25 2019-01-15 Caelus Pharmaceuticals B V uso de i. butyriciproducens e/ou e. hallii, e, composição
KR20180133443A (ko) * 2016-04-11 2018-12-14 바게닝겐 유니버시테이트 신규한 세균 종
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP2021532097A (ja) * 2018-07-19 2021-11-25 ペンデュラム セラピューティクス， インコーポレイテッド 微生物生着のための方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
RU2613322C2 (ru) 2011-08-30 2017-03-15 Академис Медис Сентрум Способ профилактики и/или лечения инсулинорезистентности
HUE043154T2 (hu) 2011-09-29 2019-08-28 Seattle Genetics Inc Proteinnel konjugált hatóanyag vegyületek intakt tömegének meghatározására
US20140242654A1 (en) 2013-02-26 2014-08-28 Coskata, Inc. Butyrate Producing Clostridium species, Clostridium pharus
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
KR101470995B1 (ko) * 2013-08-30 2014-12-09 주식회사 바이오리쏘스 프로피온산 생산능을 갖는 미생물 및 그를 포함하는 조사료 조성물
CN107405369A (zh) 2015-01-09 2017-11-28 瓦赫宁根大学 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
DK3397748T3 (da) 2015-12-31 2021-05-10 Caelus Pharmaceuticals B V Fremgangsmåde til dyrkning og konservering af Eubacterium hallii
BR112018017233A2 (pt) 2016-02-25 2019-01-15 Caelus Pharmaceuticals B V uso de i. butyriciproducens e/ou e. hallii, e, composição

Also Published As

Publication number Publication date
EP3419637B1 (en) 2021-01-27
KR20180113535A (ko) 2018-10-16
CA3014525A1 (en) 2017-08-31
ES2865477T3 (es) 2021-10-15
JP2019506413A (ja) 2019-03-07
CN108697742A (zh) 2018-10-23
EP3419637A1 (en) 2019-01-02
US10857189B2 (en) 2020-12-08
JP2022031800A (ja) 2022-02-22
AU2017222990A1 (en) 2018-09-20
SG11201807023QA (en) 2018-09-27
RU2730870C2 (ru) 2020-08-26
JP7012651B2 (ja) 2022-01-28
US20190038678A1 (en) 2019-02-07
WO2017146580A1 (en) 2017-08-31
RU2018133333A3 (pt) 2020-03-25
RU2018133333A (ru) 2020-03-25
JP7219801B2 (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112018016001A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
GT201700246A (es) Métodos y kits para tratar la depresión
CL2015003442A1 (es) Derivados heterociclicos
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BRPI0819323B8 (pt) composição à base de bactéria probiótica em associação com uma prebiótica e uso da mesma na prevenção e/ou tratamento de patologias respiratórias e/ou infecções e no aperfeiçoamento de funcionalidade intestinal
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2659 DE 21-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.